Gastrointestinal pathology research has increasingly pivoted away from broad-spectrum immunosuppressants toward highly targeted, localized interventions. In 2026, the tripeptide KPV (Lysine-Proline-Valine) has emerged as a premier candidate in the study of mucosal inflammation, Crohn’s disease models, and ulcerative colitis research. Derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH), KPV delivers potent anti-inflammatory effects without […]
